Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After an FAERS cluster in a demographic the trials under-enrolled, 505(b)(2) literature-to-product bridge table is the working evidence for regulatory-affairs lead in a safety team sitting on a new disproportionate signal. Decide whether to drop a secondary endpoint that will dominate the AdCom using only what 505(b)(2) literature-to-product bridge table actually supports.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol, Pause the pathway, Escalate safety review, Hold using 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled. The question on that file is whether to drop a secondary endpoint that will dominate the AdCom.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after an FAERS cluster in a demographic the trials under-enrolled for regulatory-affairs lead. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision to drop a secondary turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - CMC and Development Pathways finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform - Missing page in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled, if any